Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH(TM) Launch and Commercial Growth

Stock Information for Iterum Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Iterum Therapeutics plc

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Iterum Therapeutics Announces Partnership for Commercialization Services
Iterum Therapeutics Announces Extension of Term of Promissory Note
Iterum Therapeutics Reports First Quarter 2025 Financial Results
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.